Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $60.88

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been given a consensus rating of "Hold" by the twenty-five research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $60.88.

Several research analysts have issued reports on SRPT shares. Wells Fargo & Company lowered their price objective on shares of Sarepta Therapeutics from $100.00 to $75.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 17th. William Blair reiterated a "market perform" rating on shares of Sarepta Therapeutics in a research note on Friday, June 20th. Needham & Company LLC dropped their price target on Sarepta Therapeutics from $125.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday, June 16th. HC Wainwright reaffirmed a "sell" rating on shares of Sarepta Therapeutics in a research report on Wednesday. Finally, Royal Bank Of Canada lowered their target price on Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating on the stock in a research note on Wednesday, May 7th.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently bought and sold shares of SRPT. Byrne Asset Management LLC purchased a new stake in Sarepta Therapeutics during the first quarter worth $30,000. Center for Financial Planning Inc. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth $31,000. Ancora Advisors LLC boosted its position in shares of Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after buying an additional 300 shares in the last quarter. Steward Partners Investment Advisory LLC grew its stake in Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 194 shares during the last quarter. Finally, Banque Transatlantique SA acquired a new stake in Sarepta Therapeutics in the 1st quarter valued at about $44,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Performance

Shares of SRPT traded down $0.12 during midday trading on Wednesday, reaching $17.11. 4,725,991 shares of the stock were exchanged, compared to its average volume of 2,139,510. Sarepta Therapeutics has a twelve month low of $16.97 and a twelve month high of $162.95. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -6.36 and a beta of 0.61. The business's 50-day moving average price is $39.48 and its 200 day moving average price is $78.80.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The company's quarterly revenue was up 80.2% on a year-over-year basis. During the same period last year, the firm earned $0.73 EPS. On average, sell-side analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.